NVT ALLEGRA TAVI System TF in Failing Calcified Aortic Heart Valves in a Real-world Patient Population

NCT03613246 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 346

Last updated 2025-11-17

No results posted yet for this study

Summary

The study collects real-world data of patients who were treated with the ALLEGRA TAVI System TF and evaluates early and midterm clinical and quality of life outcome.

Conditions

  • Transcatheter Aortic Valve Implantation

Sponsors & Collaborators

  • NVT GmbH

    lead INDUSTRY

Principal Investigators

  • Ulrich Schäfer, MD · Herz-und Gefäßzentrum Bad Bevensen, Germany

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-20
Primary Completion
2024-12-20
Completion
2029-01-26

Countries

  • Finland
  • Germany
  • Italy
  • Netherlands
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03613246 on ClinicalTrials.gov